Itamar Medical Announces that Publication on the Role of Obstructive Sleep Apnea in Atrial Fibrillation Selected for Inclusion in Circulation’s 2018 Year in Review

Selection as one of the most prominent and important articles of 2018 reflects significant contribution to advancing cardiovascular health

CAESAREA, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that an article previously published in Circulation1 has been selected for inclusion in the journal’s 2018 Year in Review. This review, which appears in the February 2019 issue of Circulation: Arrhythmia and Electrophysiology, comprises the most important and prominent articles of 2018, as determined by the journal’s editors.

The article, titled “Atrial Substrate and Triggers of Paroxysmal Atrial Fibrillation in Patients with Obstructive Sleep Apnea,” by Dr. Elad Anter, was the first to demonstrate that obstructive sleep apnea (OSA) is associated with structural and functional remodeling of the atria. The study also showed that the presence of additional extra-PV triggers was significantly greater in patients with OSA, and most importantly, ablation of those extra non PV triggers during the procedure resulted in better outcome measured as freedom from Atrial Fibrillation 12 months after ablation supporting the strategy of screening newly diagnosed AF patients for OSA.

“The high prevalence of OSA in patients with AF, estimated at 49%, coupled with the increased incidence of non-pulmonary vein triggers underscores the need for conducting sleep studies in all AF patients as part of designing an ablation strategy,” said Gilad Glick, President and CEO of Itamar Medical. “The inclusion of this article in the 2018 Year in Review issue of one of the most prominent cardiology journals reflects the importance of these findings for effectively managing AF patients and reducing the risk for recurrence post ablations. Itamar Medical’s WatchPAT™ device, that was used in this study, an innovative solution for the cardiology practice, enables sleep studies to be conducted effectively and cost-efficiently in the patient’s home, thereby eliminating key barriers to sleep testing that occur when patients must stay overnight in the sleep lab. There is growing appreciation within the cardiology community of the role that WatchPAT can play in effectively diagnosing OSA and enabling appropriate interventions that can improve management of AF.” 

The study, which was first published in the November 13, 2017 issue of Circulation: Arrhythmia and Electrophysiology, was conducted by clinical researchers from the Cardiovascular Division, Department of Medicine, Harvard-Thorndike Electrophysiology Institute; and Sleep Disorders Clinic, Departments of Medicine and Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School; Texas Cardiac Arrhythmia Institute, St. David’s Medical Center; and Electrophysiology Section, Cardiovascular Division, University of Miami Miller School of Medicine.

About Itamar Medical Ltd.

Itamar Medical is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory disorders with a focus on the cardiology market. The Company offers a Total Sleep Solution™ to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare costs. Its flagship PAT-based product, the WatchPAT™ device, is a home-use diagnostic device for sleep breathing disorders. It also offers the EndoPAT™ system, an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. Itamar Medical is a public company traded on the Tel Aviv Stock Exchange and is based in Caesarea, Israel. For additional information visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss growing appreciation within the cardiology community of the role of WatchPAT, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by Itamar Medical in reports filed with, or furnished to, the Israel Securities Authority and the U.S. Securities and Exchange Commission. Except as otherwise required by law, Itamar Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.


1 Anter E, Di Biase L, Contreras-Valdes MF, Gianni C, Mohanty S, Tschabrunn CM, et al. Atrial Substrate and Triggers of Paroxysmal Atrial Fibrillation in Patients with Obstructive Sleep Apnea. Circ Arrhythm Electrophysiol. 2017;10:e005407.


David Carey
Lazar Partners Ltd.

Eran Gabay
Galbert-Kahana Investor Relations and Public Relations